发明公开
EP3280729A2 CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL
审中-公开
CD20疗法，CD22疗法和与CD19嵌合抗原接受者（CAR）的组合疗法 - 表达细胞
- 专利标题： CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL
- 专利标题（中）： CD20疗法，CD22疗法和与CD19嵌合抗原接受者（CAR）的组合疗法 - 表达细胞
-
申请号： EP16719611.2申请日： 2016-04-08
-
公开(公告)号： EP3280729A2公开(公告)日： 2018-02-14
- 发明人: BITTER, Hans , BORDEAUX, Jennifer, Mary , BRANNETTI, Barbara , BROGDON, Jennifer , DAKAPPAGARI, Naveen, Kumar , GILL, Saar , HIGHFILL, Steven , HUANG, Lu , JUNE, Carl, H. , KIM, Ju, Young , LEI, Ming , LI, Na , LOEW, Andreas , ORLANDO, Elena , RUELLA, Marco , TRAN, Thai , ZHANG, Jimin , ZHOU, Li
- 申请人： Novartis AG , The Trustees of The University of Pennsylvania
- 申请人地址： Lichtstrasse 35 4056 Basel CH
- 专利权人： Novartis AG,The Trustees of The University of Pennsylvania
- 当前专利权人： Novartis AG,The Trustees of The University of Pennsylvania
- 当前专利权人地址： Lichtstrasse 35 4056 Basel CH
- 代理机构： Wilding, James Roger
- 优先权： US201562144639P 20150408; US201562144615P 20150408; US201562144497P 20150408; US201562207255P 20150819; US201562263423P 20151204
- 国际公布： WO2016164731 20161013
- 主分类号： C07K14/725
- IPC分类号： C07K14/725 ; C07K16/28 ; C12N5/0783 ; A61K39/00
摘要：
The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
公开/授权文献
信息查询
